Description: Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an opportunity to advance the course of cancer care.
Home Page: www.centurytx.com
IPSC Technical Analysis
3675 Market Street
Philadelphia,
PA
19104
United States
Phone:
267 817 5790
Officers
| Name | Title |
|---|---|
| Dr. Osvaldo Flores Ph.D. | Pres, CEO & Director |
| Dr. Adrienne Farid Ph.D. | Chief Operations Officer |
| Dr. Luis Borges | Chief Scientific Officer |
| Mr. Douglas Carr CPA | VP of Fin. and Operations & Sec. |
| Dr. Gregory Russotti Ph.D. | Chief Technology Officer |
| Mr. Kenneth J. Dow J.D. | Head of Legal & Compliance |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Dr. Michael C. Diem | Chief Bus. Officer |
| Dr. Hyam I. Levitsky M.D. | Pres of R&D |
| Mr. Mark Wallet | Head of Immunology & VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 47.8 |
| Price-to-Book MRQ: | 1.5109 |
| Price-to-Sales TTM: | 102.4926 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 170 |